{"url":"https://lda.senate.gov/api/v1/filings/b1f407e4-2cb3-4404-90f7-e2cfa338273c/","filing_uuid":"b1f407e4-2cb3-4404-90f7-e2cfa338273c","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2025,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/b1f407e4-2cb3-4404-90f7-e2cfa338273c/print/","filing_document_content_type":"text/html","income":null,"expenses":"880000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Courtney Piron","dt_posted":"2025-07-21T09:41:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"801 PENNSYLVANIA AVENUE, NW","registrant_address_2":"Suite 700","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":9204,"url":"https://lda.senate.gov/api/v1/registrants/9204/","house_registrant_id":33589,"name":"NOVARTIS","description":"Federal Government Relations/Legislative Affairs","address_1":"801 Pennsylvania Avenue, NW","address_2":"Suite 700","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"COURTNEY PIRON","contact_telephone":"+1 202-662-4364","dt_updated":"2026-07-22T10:55:30.763850-04:00"},"client":{"id":113305,"url":"https://lda.senate.gov/api/v1/clients/113305/","client_id":12,"name":"NOVARTIS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2010-12-07"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Funding for FDA - FY 2026 Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act 2026 FY 2026 President's Budget Request Inflation Reduction Act of 2022 (P.L. 117-169) Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 Federal Budget Funding for National Institutes of Health - FY 2026 Appropriations H.R. 1: One Big Beautiful Bill Act (P.L. 119-21)","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent eligibility policy issues H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act)","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program Accelerated Approval Breast Cancer Research Breast Cancer Diagnostics H.R.3037, Access to Breast Cancer Diagnostic Act of 2025 S.1500, Access to Breast Cancer Diagnostic Act of 2025 Alternative Funding Programs Supply Chain Integrity and Traceability PBM Reform Modernizing and Ensuring PBM Accountability (MEPA) Act Coverage of Accelerated Approval Products Drug Benefit Design Orphan Drug Issues H.R.946: ORPHAN Cures Act H.R. 1262: Give Kids a Chance Act of 2025 Innovation in Pediatric Drugs Act S.864: HELP Copays Act Reimbursement and Coverage of Innovative Products Lower Costs, More Transparency Act Lower Costs, More Cures Act Medicare Part B Physician-Administered Products Patient Cost-Sharing and Smoothing Step Therapy Support of Patient Premiums and Cost-Sharing Obligations Value-based Contracting and Communications H.R. 2214: DRUG Act User fee policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues FDA regulatory approval authority policy issues Competition policy issues Clinical trial diversity policy issues Drug shortages policy issues Artificial intelligence policy issues IRA price negotiation expansion policy issues Rare Pediatric Disease Priority Review Voucher program policies SUSTAIN RFI/discussion draft Most Favored Nation policy","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 950: Saving Seniors Money on Prescriptions Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues S. 832/H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025 Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Domestic and International Tax Policy Issues Research & Development Tax Credit Reforms Tax Relief for American Families and Workers Act Foreign Direct Investment Expensing of R&D Expenditures H.R. 2425 - Unfair Tax Prevention Act of 2025 Tax Cuts and Jobs Act, PL 115-97 H.R. 1: One Big Beautiful Bill Act (P.L. 119-21)","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152572,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":"ANDREW","last_name":"SUTER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues US Swiss Trade Agreement US Trade Policy","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"Anti-Trust Reform","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}